Protagonist Therapeutics (NASDAQ: PTGX) reported Q2 EPS of ($0.50), $0.10 better than the analyst estimate of ($0.60). Revenue for the quarter came in at $4.17 million versus the consensus estimate of $68 million.

For earnings history and earnings-related data on Protagonist Therapeutics (PTGX) click here.